US FDA weighs in on regulating cannabis compound CBD in foods and supplements – WSJ

Dec 27 (Reuters) – The U.S. Food and Drug Administration (FDA) plans to make recommendations on how to regulate the use of the popular cannabis compound CBD in foods and supplements, The Wall Street reported on Tuesday. Newspaper, citing agency officials.

After weighing the evidence for the compound’s safety, the FDA will decide in a few months how to regulate legal cannabis and whether it will require new agency rules or new congressional legislation, according to the report.

Cannabidiol, or CBD, is a non-psychoactive compound derived from cannabis.

Cannabis products, with the exception of Epidiolex from Jazz Pharmaceuticals PLC (JAZZ.O), are federally illegal in the United States, although some states allow their use.

The agency wants to know if CBD can be safely consumed every day for a long time or during pregnancy amid concerns about future fertility, said Patrick Cournoyer, who leads the FDA office developing the strategy. the cannabis agency, at the WSJ.

When asked for comment, the FDA referred Reuters to a statement from last year that said the agency was taking steps to improve regulatory pathways for the legal marketing of appropriate cannabis and cannabis-derived products.

Reporting by Raghav Maobe in Bengaluru; Editing by Devika Syamnath

Our standards: The Thomson Reuters Trust Principles.

Leave a Comment